NEW BRUNSWICK, N.J. – Johnson & Johnson has announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020; the significant expansion of the existing partnership between the Janssen Pharmaceutical Companies of Johnson & Johnson and the Biomedical Advanced Research and Development Authority (BARDA); and the rapid scaling of
NEW BRUNSWICK, N.J. — Dominic Caruso, executive vice president and chief financial officer at Johnson & Johnson, is slated to retire this fall and be succeeded by Joseph Wolk. The company said late Tuesday that Caruso, who plans to retire in September, has served as Johnson & Johnson CFO longer than anyone in its 132- year
NEW BRUNSWICK, N.J. — Johnson & Johnson has reached an agreement to acquire Switzerland-based biopharmaceutical company Actelion Ltd. for $30 billion in cash. J&J said Actelion’s differentiated, innovative products for pulmonary arterial hypertension (PAH) are highly complementary to the portfolio of the Janssen Pharmaceutical Companies of Johnson & Johnson. The company also noted that the
